The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial registered on ANZCTR


Registration number
Help: Registration number
ACTRN12626000448347
Ethics application status
Help: Ethics application status
Approved
Date submitted
Help: Date submitted
15/03/2026
Date registered
Help: Date registered
10/04/2026
Date last updated
Help: Date last updated
10/04/2026
Date data sharing statement initially provided
Help: Data sharing statement date
10/04/2026
Type of registration
Help: Type of registration
Prospectively registered

Titles & IDs
Public title
COPD OUT- Does dosage of physiotherapy management of acute exacerbation of Chronic Obstructive Pulmonary Disease affect OUTcomes?
Scientific title
COPD OUT- Does dosage of physiotherapy management of acute exacerbation of Chronic Obstructive Pulmonary Disease affect OUTcomes? A pilot feasibility trial
Additional trial identifiers [1] 316576 0
None
Universal Trial Number (UTN)
Trial acronym
COPD OUT
Related trial records

Health condition
Health condition(s) studied:
Acute exacerbation of chronic obstructive pulmonary disease 340752 0
Condition category
Condition code
Respiratory 336933 336933 0 0
Chronic obstructive pulmonary disease
Physical Medicine / Rehabilitation 336934 336934 0 0
Physiotherapy

Intervention/exposure
Study type
Interventional
Description of the intervention or exposure
Arm 1 participants (Physio-Lite) receive a standard physiotherapy program but with lower intensity. This comprises of patient assessment (assess), education (talk), ambulation only (walk) and encouragement to cough to clear (breathe). The intervention ceases upon the participant’s discharge from physiotherapy or hospital or if any other endpoint is reached. Total duration of an initial session is estimated to be 40 - 55 minutes.

Assess: Participants with receive during their first physiotherapy session an initial respiratory assessment, full social and functional history assessment including early identification of barriers to discharge (approximately 10 - 15 minutes).

Talk:
Participants will have a single face-to-face education session during their initial assessment with their physiotherapist (approximately 15 - 20 minutes). During this session, participants will be educated on the role of physiotherapy in managing a flare-up of COPD. Participants will be educated on the benefit of walking, exercise, and coughing to prevent deconditioning and potential further respiratory deterioration. Additionally, participants will receive education about the contributors to breathlessness and be educated how best to manage this. This will include discussion about pursed lip breathing and recovery positions.
Participants will be encouraged to sit out of bed, move around the bed space, and walk away from their bedside (if safe to do so) as able outside of their physiotherapy session with appropriate supervision.
This information can also be provided ad hoc if requested by the participant during any session, but it will not be prompted.

Walk:
Mobilisation every second day for up to 10 minutes total.
Initiation: As soon as clinically appropriate after admission.
Duration: Up to 10 minutes total work time per session.
Frequency: Once every second day until discharged from physiotherapy.
Intensity: Gentle activity aiming for a moderate level of breathlessness (rated as “slightly breathless” to “moderately breathless” on the Borg scale, approximately 3–4/10).
Type: Continuous walking for at least 1 minute, building up to 10 minutes as able. Walking can be performed in intervals with equal rest breaks (1:1 work-to-rest ratio).
Mode: Ambulation only. At every session the participant will be progressed sequentially through the protocol stages aiming to achieve a walking time of up to 10-minutes. Successful ambulation is defined as continuously marching on the spot beside the bed or walking away from the bedside for more than one minute. If a participant is unable to participate in upright ambulation then no other non-ambulation exercises will be provided that day.

Breathe:
Participants will receive a daily respiratory assessment and encouragement to cough to clear their chest (approximately 5 - 10 minutes). No other respiratory physiotherapy interventions will be provided by the physiotherapist, this includes, but is not limited to, the following; manual techniques, positive expiratory pressure devices, incentive spirometers, mechanical insufflation-exsufflation, or non-invasive ventilation.
If a participant has a pre-existing airway clearance regime it may be continued, but it will not be encouraged.

In both arms, the patient can be considered discharged from physiotherapy when they score greater than or equal to 8 according to the ECOPD DST – Exacerbation of COPD Discharge Screening Tool.
Once the patient is discharged from physiotherapy and deemed medically suitable for discharge, they will be reviewed again by a blinded physiotherapist to receive standardised education regarding the benefits of pulmonary rehabilitation and be offered a referral to the program.
On the seventh day, if the participant is still in the hospital, a blinded senior physiotherapist will review the participant's progress notes within the medical record and adjudicate the requirement for ward-based or residential rehabilitation services.
As all intervention sessions are physiotherapist-supervised, adherence will be defined as successful delivery of the prescribed treatment components. Adherence will be recorded on standardised ward data collection sheets completed by the treating physiotherapist at each session.
Intervention code [1] 333254 0
Rehabilitation
Intervention code [2] 333531 0
Treatment: Other
Description of the comparator or control
Arm 2 participants (Physio-Plus) receive a standard physiotherapy program with higher intensity. This comprises of patient assessment (assess), education (talk), ambulation and early rehabilitation (walk) and supervised chest physiotherapy (breathe). The intervention ceases upon the participant’s discharge from physiotherapy or hospital or if any other endpoint is reached. Total duration of an initial session is estimated to be 65 - 80 minutes.

Assess: Participants with receive during their first physiotherapy session an initial respiratory assessment, full social and functional history assessment including early identification of barriers to discharge (approximately 10 - 15 minutes).

Talk:
Participants will have a single face-to-face education session during their initial assessment with their physiotherapist. During this session, participants will be educated on the role of physiotherapy in managing a flare-up of COPD. Participants will be educated on the benefit of walking, exercise, and coughing to prevent deconditioning and potential further respiratory deterioration. Additionally, participants will receive education about the contributors to breathlessness and be educated how best to manage this. This will include discussion about pursed lip breathing and recovery positions (approximately 15 - 20 minutes).
Participants will be encouraged to sit out of bed, move around the bed space, and walk away from their bedside (if safe to do so) as able outside of their physiotherapy session with appropriate supervision. This information can also be provided ad hoc if requested by the participant during any session, but it will not be prompted.

Walk:
Mobilisation every day aiming for 30 minutes total.
Initiation: As soon as clinically appropriate after admission.
Duration: Aiming for 30 minutes total work time per session.
Frequency: Once every day until discharged from physiotherapy.
Intensity: Gentle activity aiming for a moderate level of breathlessness (rated as “slightly breathless” to “moderately breathless” on the Borg scale, approximately 3–4/10).
Type: Continuous walking for at least 1 minute, building up to 30 minutes as able. Walking can be performed in intervals with equal rest breaks (1:1 work-to-rest ratio).
Mode: Functional exercise program starting with ambulation as per the control group protocol aiming for 30 minutes of walking. If walking time is less than 30 minutes, non-ambulatory physical activity is continued to be provided until the 30 minutes of activity time is achieved (including rest periods). Physical activity is provided in a sequential step-down process starting with the highest activity possible and moving to less intense. These exercises consist of chair or bed based progressive low resistance, high repetition, lower and upper limb exercises as prescribed by the treating physiotherapist based on the individual patient’s requirements and functional ability. If this falls on a weekend or public holiday, the patient will be provided with education and encouragement to continue their current program independently.

Breathe:
Participants will receive a daily respiratory assessment and airway clearance practice as determined by the physiotherapist (approximately 10 - 15 minutes). Airway clearance will be provided at the discretion of the physiotherapist and individually tailored. If appropriate, participants will be encouraged to individually complete their airway clearance regime.

In both arms, the patient can be considered discharged from physiotherapy when they score greater than or equal to 8 according to the ECOPD DST – Exacerbation of COPD Discharge Screening Tool.
Once the patient is discharged from physiotherapy and deemed medically suitable for discharge, they will be reviewed again by a blinded physiotherapist to receive standardised education regarding the benefits of pulmonary rehabilitation and be offered a referral to the program.
On the seventh day, if the participant is still in the hospital, a blinded senior physiotherapist will review the participant's progress notes within the medical record and adjudicate the requirement for ward-based or residential rehabilitation services.
As all intervention sessions are physiotherapist-supervised, adherence will be defined as successful delivery of the prescribed treatment components. Adherence will be recorded on standardised ward data collection sheets completed by the treating physiotherapist at each session.
Control group
Active

Outcomes
Primary outcome [1] 344494 0
Feasibility of recruitment
Timepoint [1] 344494 0
Screening and enrolment logs reviewed continuously throughout the trial; reported as a cumulative summary on study completion.
Primary outcome [2] 344495 0
Feasibility of data collection
Timepoint [2] 344495 0
Assessed continuously throughout the trial; reported as a cumulative summary on study completion (data collection windows: in-hospital Days 1–7, on discharge, three months, and six months post-discharge).
Primary outcome [3] 344496 0
Feasibility of treatment protocols
Timepoint [3] 344496 0
Assessed throughout the first seven days of admission or until discharge from physiotherapy, whichever occurs first; reported as a cumulative summary on study completion.
Secondary outcome [1] 458034 0
Feasibility — Separation between groups (Note: Primary feasibility outcome)
Timepoint [1] 458034 0
Measured daily across the first seven days of admission (or until discharge from physiotherapy, whichever occurs first); reported as a cumulative summary on study completion.
Secondary outcome [2] 458035 0
Feasibility - Safety of treatment protocols (Note: Primary outcome)
Timepoint [2] 458035 0
During each physiotherapy session throughout the first seven days of admission; reported cumulatively on study completion.
Secondary outcome [3] 458036 0
Total hospital days sub-categorised into acute, sub-acute, and overall length of stay
Timepoint [3] 458036 0
Total days in hospital from admission to community discharge, assessed at the conclusion of the acute and (where applicable) sub-acute admission
Secondary outcome [4] 458037 0
Medical team requests for extra rehabilitation or respiratory physiotherapy
Timepoint [4] 458037 0
Continuously monitored across the first seven days of admission; adjudicated by a blinded senior physiotherapist by Day 7 (or earlier if a referral is received).
Secondary outcome [5] 458038 0
Discharge destination from the acute ward
Timepoint [5] 458038 0
On discharge from the acute ward
Secondary outcome [6] 458039 0
Physical recovery — Rate of change of the Modified Iowa Level of Assistance (mILOA)
Timepoint [6] 458039 0
Measured second daily from first available assessment (Day 1 of admission or earliest clinically feasible date) through to Day 7 of admission or discharge from physiotherapy.
Secondary outcome [7] 458040 0
Physical recovery — Rate of change of the Breathlessness, Cough and Sputum Scale (BCSS)
Timepoint [7] 458040 0
Assessed daily across the first seven days of admission until discharge from physiotherapy, on discharge from physiotherapy, and at three- and six-months post-discharge via telephone interview.
Secondary outcome [8] 458041 0
Physical recovery — COPD Assessment Test (CAT)
Timepoint [8] 458041 0
On discharge from physiotherapy, and at three- and six-months post-discharge via telephone interview.
Secondary outcome [9] 458042 0
Physical recovery — modified Medical Research Council (mMRC) dyspnoea scale
Timepoint [9] 458042 0
On discharge from physiotherapy, and at three- and six-months post-discharge via telephone interview.
Secondary outcome [10] 458043 0
Physical recovery — Rate of change of grip strength
Timepoint [10] 458043 0
Measured on admission (or first available assessment), then every second day until discharge or Day 7 of admission, whichever occurs first.
Secondary outcome [11] 458044 0
Uptake of pulmonary rehabilitation
Timepoint [11] 458044 0
Referral offered and accepted: on discharge from the acute ward. Attendance and completion: assessed at three-month post-discharge telephone follow-up.
Secondary outcome [12] 458045 0
Unplanned hospital readmission within 30 days of discharge
Timepoint [12] 458045 0
30 days post-discharge will be ascertained at three-month telephone follow-up
Secondary outcome [13] 458047 0
All-cause mortality at six months
Timepoint [13] 458047 0
Six months post-discharge from the index admission.
Secondary outcome [14] 458048 0
Unplanned admission to the intensive care unit (ICU) during the index admission
Timepoint [14] 458048 0
Any time during the index acute hospital admission.
Secondary outcome [15] 458049 0
Subjective satisfaction with physiotherapy care received during the hospital admission
Timepoint [15] 458049 0
On discharge from physiotherapy
Secondary outcome [16] 458050 0
Patient-reported post-discharge complications
Timepoint [16] 458050 0
At three- and six-months post-discharge via telephone interview.
Secondary outcome [17] 458051 0
Hospital costs for the index admission episode of care
Timepoint [17] 458051 0
Assessed at conclusion of the index admission episode of care.
Secondary outcome [18] 459037 0
Unplanned commencement of non-invasive ventilation (NIV) during the index admission
Timepoint [18] 459037 0
Any time during the index acute hospital admission.
Secondary outcome [19] 459038 0
Time to discharge from the inpatient physiotherapy service
Timepoint [19] 459038 0
From Day 1 of admission through to the date of discharge from the physiotherapy service.
Secondary outcome [20] 459039 0
Blinding integrity of the outcome assessor and participant
Timepoint [20] 459039 0
On discharge from physiotherapy

Eligibility
Key inclusion criteria
Eligible participants are adults over the age 18 with a medical diagnosis of COPD meeting at least one of the following criteria:

1) Admitted with a diagnosis of an acute exacerbation of COPD characterised by:
a) A sustained worsening of the patient’s symptoms from his or her usual stable state.
b) The exacerbation is acute in onset (within 24-48 hours prior to hospital admission).

2) Admitted with a diagnosis of community-acquired pneumonia, type 1 respiratory failure, type 2 respiratory failure, or respiratory virus with a background of COPD.
Minimum age
18 Years
Maximum age
No limit
Sex
Both males and females
Healthy volunteers
No
Key exclusion criteria
Exclusion criteria are as follows:
1) Patients admitted to intensive care unit (ICU) or high-dependency unit (HDU);
2) Patients admitted with type 2 respiratory failure requiring non-invasive ventilation;
3) Previously recruited in the trial at a previous admission;
4) Patients with a medical diagnosis of bronchiectasis;
5) Admitted with confirmed SARS-CoV-2 on a positive rapid antigen test or PCR within 48 hours of admission;
6) Patients admitted for palliative management (Goals of Care C2/D);
7) Patients experiencing acute delirium.

Study design
Purpose of the study
Treatment
Allocation to intervention
Randomised controlled trial
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Each weekday morning, site investigators will utilise Patient Flow, the LGH’s electronic patient management system, to identify eligible patients for enrolment in the study. Group allocation will be concealed using online REDCap secure software. Patients will be allocated randomly on a 1:1 basis to either treatment arm 1 (Physio-Plus) or treatment arm 2 (Physio-Lite).
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Simple, non-stratified, unblocked 1:1 randomisation using a pre-prepared allocation sequence generated by computer software. Group allocation will be concealed using the online REDCap secure randomisation module
Masking / blinding
Blinded (masking used)
Who is / are masked / blinded?


The people assessing the outcomes
The people analysing the results/data
Intervention assignment
Other design features
Phase
Not Applicable
Type of endpoint/s
Statistical methods / analysis
Statistical Methods:
As this study is stratified only by physiotherapy dosage, there is a possibility of baseline imbalances between groups. These will be assessed for prognostic strength and magnitude of imbalance. Adjustment covariates will be selected using backward stepwise regression from variables with potential for clinically significant influence on outcomes. Candidate covariates include: age, sex, smoking history (pack-years), comorbidity burden (Functional Comorbidity Index), and pre-admission mobility status.

Primary Outcomes:
The primary feasibility outcomes (recruitment rate, consent rate, protocol adherence, adverse event incidence) will be summarized descriptively as proportions with 95% confidence intervals. Adverse event rates between groups will be compared using Fisher’s exact tests.

Secondary Outcomes:
Binomial outcomes including rehabilitation referrals, unplanned ICU admissions, unplanned non-invasive ventilation, patient-reported complications, and mortality will be analysed using multivariate robust random effects Poisson generalised linear regression.

Time-to-event binomial outcomes (e.g. hospital and ICU LOS; and mortality) will be compared by estimating hazard ratios using Cox proportional hazards regression, with and without covariate adjustment where necessary and graphically illustrated using Kaplan-Meier methods.

Measures involving estimation of rate of change over time (QOL and functional capacity) will be analysed using repeated-measures mixed effects linear regression or ordered logistic regression for rank-ordered scale measures.

All outcomes will be analysed on an intention-to-treat basis. An intention-to-protocol sensitivity analysis will be performed by identifying as a separate group participants who received more than 80% of planned protocol sessions as per group allocation. Other planned sensitivity analyses will be made according to age, pre-admission self-reported physical capacity, and gender. Sensitivity of outcome estimates to missing data will be evaluated using multiple imputations.

Recruitment
Recruitment status
Not yet recruiting
Date of first participant enrolment
Anticipated
Actual
Date of last participant enrolment
Anticipated
Actual
Date of last data collection
Anticipated
Actual
Sample size
Target
Accrual to date
Final
Recruitment in Australia
Recruitment state(s)
TAS
Recruitment hospital [1] 29165 0
Launceston General Hospital - Launceston
Recruitment postcode(s) [1] 45481 0
7250 - Launceston

Funding & Sponsors
Funding source category [1] 321195 0
Charities/Societies/Foundations
Name [1] 321195 0
Clifford Craig Foundation
Country [1] 321195 0
Australia
Primary sponsor type
Government body
Name
Tasmanian Department of Health
Address
Country
Australia
Secondary sponsor category [1] 323898 0
None
Name [1] 323898 0
Address [1] 323898 0
Country [1] 323898 0

Ethics approval
Ethics application status
Approved
Ethics committee name [1] 319725 0
UTS Human Research Ethics Committee
Ethics committee address [1] 319725 0
Ethics committee country [1] 319725 0
Australia
Date submitted for ethics approval [1] 319725 0
13/03/2026
Approval date [1] 319725 0
19/03/2026
Ethics approval number [1] 319725 0

Summary
Brief summary
Trial website
Trial related presentations / publications
Public notes

Contacts
Principal investigator
Name 148190 0
Dr Ianthe Boden
Address 148190 0
Physiotherapy Department Launceston General Hospital PO Box 1963 Launceston, Tasmania 7250
Country 148190 0
Australia
Phone 148190 0
+61 3 6348 7216
Fax 148190 0
Email 148190 0
Contact person for public queries
Name 148191 0
Ianthe Boden
Address 148191 0
Physiotherapy Department Launceston General Hospital PO Box 1963 Launceston, Tasmania 7250
Country 148191 0
Australia
Phone 148191 0
+61 3 6348 7216
Fax 148191 0
Email 148191 0
Contact person for scientific queries
Name 148192 0
Ianthe Boden
Address 148192 0
Physiotherapy Department Launceston General Hospital PO Box 1963 Launceston, Tasmania 7250
Country 148192 0
Australia
Phone 148192 0
+61 3 6348 7216
Fax 148192 0
Email 148192 0

Data sharing statement
Will the study consider sharing individual participant data?
Yes
Will there be any conditions when requesting access to individual participant data?
Persons/groups eligible to request access:
• Researchers
Conditions for requesting access:
• No requirements
What individual participant data might be shared?
• All de-identified individual participant data
What types of analyses could be done with individual participant data?
• Any type of analysis (i.e. no restrictions on data re-use)
When can requests for individual participant data be made (start and end dates)?
From:
After publication of main results
To:
No end date
Where can requests to access individual participant data be made, or data be obtained directly?
• Access subject to new data sharing agreement and ethical/institutional review board clearance to share deidentified data. Please contact the principal investigator via email for any data access requests via [email protected]

Are there extra considerations when requesting access to individual participant data?
No


What supporting documents are/will be available?

No Supporting Document Provided


Results publications and other study-related documents

Documents added manually
No documents have been uploaded by study researchers.

Documents added automatically
No additional documents have been identified.